Table 2.
Decrease in NFL level in response to disease-modifying therapies.
| Reference # | DMT | QR-NFL |
|---|---|---|
| (88) | Natalizumab | 37% |
| (95) | IFN or glatiramer acetate switch to rituximab | 21% |
| (90) | Natalizumab | 20% |
| (89) | Fingolimod | 33% |
| (85) | Natalizumab | <16 pg/mL |
| (15) | Fingolimod vs IFNβ1α | 38% |
| (94) | Ibudilast | ND |
ND, No difference; QR-NFL, quantitative reduction in NFL.